Skip to main content

Table 1 Characters of included 32 papers about the prognostic value of miR-221 in human carcinomas

From: Prognostic value of miR-221 in human malignancy: evidence from 3041 subjects

Study Nation Patients cancer Survival HR(95% CI) P value Origins Measure Cutoff Analysis
Wu Q (2017) China 74 Ovarian cancer OS 0.395 (0.196–0.796) 0.009 Tumor qRT-PCR Median Univariate
Tsikrika (2017) Greece 159 Bladder cancer DFS
PFS
0.712(0.380–1.335)
1.396(0.539–3.620)
0.290
0.492
Tumor qRT-PCR ROC Univariate
Deng (2017) China 125 Breast cancer DFS 0.480 (0.263–0.879) 0.017 Tumor qRT-PCR Median Multivariate
Nakka (2017) USA 32 Osteosarcoma OS 0.733(0.486–1.1055) 0.139 Tumor qRT-PCR/ISH Quartation Multivariate
Xie D (2017) China 70 Live cancer OS 1.743 (1.004–3.772) 0.012 Tumor qRT-PCR Median Multivariate
Hussein (2017) Egypt 50 Laryngeal cancer OS 6.5 (1.8–22.5) 0.003 Tumor qRT-PCR ROC Univariate
Dai L (2017) China 78 Thyroid cancer RFS 1.41(1.14–1.95) 0.007 Tumor qRT-PCR Median Multivariate
Chen F (2017) China 135 HCC DFS
OS
2.846 (1.564–5.181)
2.969 (1.629–5.408)
0.001
< 0.001
Tumor qRT-PCR Median Multivariate
Zhang Y (2016) China 104 Lung cancer OS 1.873(1.267–2.768) 0.002 Tumor qRT-PCR Median Multivariate
Yang Z (2015) China 108 Osteosarcoma OS
RFS
7.66(1.83–15.92)
6.82(1.33–13.69)
0.01
0.01
Serum qRT-PCR Median Multivariate
Cai K (2015) China 182 Colon cancer OS 2.394 (1.210–4.910) 0.006 Tumor qRT-PCR Median Multivariate
Tao K (2014) China 90 Colon cancer OS 2.043 (1.095–3.812) 0.025 Tumor qRT-PCR Median Multivariate
Vergho (2014) Germany 74 Renal cancer CSS 0.47 (0.22–1.00) 0.0527 Tumor qRT-PCR ROC Multivariate
Lv J (2014) China 117 Lung cancer OS 2.425 (1.314–4.475) 0.005 Tumor qRT-PCR Median Multivariate
Li P (2014) China 72 CMM OS
DFS
3.189(1.782–6.777)
2.119(1.962–8.552)
0.007
0.01
Serum qRT-PCR Median Multivariate
Gyongyosi B (2014) Italy 20 HCC OS
PFS
1.92(0.61–6.10)
1.32(0.47–3.66)
0.29
0.58
Tumor qRT-PCR Median Univariate
Falkenberg (2013) Germany 86 Breast cancer MFS 2.57(1.1073–5.9647) 0.028 Tumor qRT-PCR ROC Multivariate
Hong (2013) China 96 Ovarian cancer OS 2.243(1.1357–4.4300) 0.020 Serum qRT-PCR Mean Multivariate
Gimenes (2013) Brazil 48 ALL OS
DFS
2.31(0.92–5.81)
1.54 (0.57–4.17)
0.074
0.391
Marrow qRT-PCR Median Multivariate
Karakatsanis (2013) Greece 60 HCC OS 1.72 (1.32–2.50) 0.002 Tumor qRT-PCR Mean Multivariate
Amankwah (2013) USA 65 Prostate cancer RFS 1.79 (0.67–4.76) 0.25 Tumor qRT-PCR Median Multivariate
Liu K (2012) China 92 Gastric cancer OS 2.322 (1.1116–4.8505) 0.025 Tumor qRT-PCR Mean Multivariate
Hanna (2012) USA 377 Breast cancer OS 0.70 (0.51–0.97) 0.0312 Tumor ISH Quartation Multivariate
Kang (2012) Korea 92 Prostate cancer RFS 0.360 (0.171–1.896) 0.570 Tumor qRT-PCR Median Univariate
Li J (2011) China 46 HCC OS 1.903(1.235–2.981) 0.018 Serum qRT-PCR Mean Multivariate
Yoon (2011) Korea 115 HCC RFS 3.07 (1.56–6.07) 0.001 Tumor qRT-PCR Mean Multivariate
Zhao R (2011) China 93 Breast cancer OS 6.871 (1.967–23.997) 0.003 plasma qRT-PCR Median Multivariate
Schaefer (2010) Germany 75 Prostate cancer RFS 0.93 (0.3–2.89) 0.902 Tumor qRT-PCR Median Univariate
Wang (2010) China 32 ALL OS 0.538(0.30–0.9648) 0.038 Marrow qRT-PCR Median Multivariate
Spahn (2010) Germany 92 Prostate cancer RFS 0.525(0.29–0.95) 0.032 Tumor qRT-PCR ROC Multivariate
Pu (2010) China 103 Colon cancer OS 3.478(1.038–11.654) 0.043 Plasma qRT-PCR Youden Multivariate
Guo (2010) China 79 Lymphoma OS 5.714(1.782–18.18) 0.003 Plasma qRT-PCR Youden Multivariate
  1. Note: HCC Hepatocellular carcinoma; ALL Acute lymphoid leukemia; CMM Cutaneous malignant melanoma; ROC Receiver operating characteristic curve; Youden, Youden index; OS Overall survival; RFS Relapse-free survival; DFS Disease-free survival; PFS Progression-free survival; CSS Cancer-special survival; MFS Metastasis-free survival; qRT-PCR Quantitative Real Time PCR; ISH In-situ hybridization